Education
About Us
Working with TipRanks
Follow Us
Autolus Therapeutics Plc (AUTL)
NASDAQ:AUTL
AUTL Stock Chart & Stats
$1.60
-$0.14(-5.56%)
At close: 4:00 PM EST
$1.60
-$0.14(-5.56%)
Day’s Range― - ―
52-Week Range$1.11 - $2.80
Previous CloseN/A
Volume359.61K
Average Volume (3M)3.38M
Market Cap
$425.83M
Enterprise Value$390.08M
Total Cash (Recent Filing)$367.41M
Total Debt (Recent Filing)$65.83M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Mar 10, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding266,143,280
10 Day Avg. Volume2,715,558
30 Day Avg. Volume3,380,173
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.40
Price to Sales (P/S)59.25
P/FCF Ratio-2.49
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue7.63
Enterprise Value/Gross Profit-2.47
Enterprise Value/Ebitda-1.55
Forecast
1Y Price Target
$7.68Price Target Upside380.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.92
Revenue Forecast (FY)$75.21M
Bulls Say, Bears Say
Bulls Say
Market ExpansionMarket expansion into pediatric ALL and lupus nephritis can push Aucatzyl to blockbuster market opportunity, and the differentiated safety and efficacy profile of Aucatzyl will continue to drive market share conversion.
Product Safety ProfileThe real-world analysis showed all patients received both doses of Aucatzyl, and physicians were comfortable treating older patients with Aucatzyl than Tecartus, suggesting strong market share gains since commercial launch.
Regulatory ProgressObe-cel for pediatric patients received RMAT designation.
Bears Say
Clinical UncertaintyIt remains unclear if longer B-cell aplasia translates into more durable clinical responses.
Sales PerformanceSales were flat due to changes in CMS leading to a slowdown in patients.
Stock PerformanceAutolus shares are down roughly 13% following the earnings release, with sales coming in below consensus in the quarter and yet COGS coming in above estimates.
Autolus Therapeutics News
AUTL FAQ
What was Autolus Therapeutics Plc’s price range in the past 12 months?
Autolus Therapeutics Plc lowest stock price was $1.10 and its highest was $2.80 in the past 12 months.
What is Autolus Therapeutics Plc’s market cap?
Autolus Therapeutics Plc’s market cap is $425.83M.
When is Autolus Therapeutics Plc’s upcoming earnings report date?
Autolus Therapeutics Plc’s upcoming earnings report date is Mar 10, 2026 which is in 82 days.
How were Autolus Therapeutics Plc’s earnings last quarter?
Autolus Therapeutics Plc released its earnings results on Nov 12, 2025. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.214 by -$0.086.
Is Autolus Therapeutics Plc overvalued?
According to Wall Street analysts Autolus Therapeutics Plc’s price is currently Undervalued.
Does Autolus Therapeutics Plc pay dividends?
Autolus Therapeutics Plc does not currently pay dividends.
What is Autolus Therapeutics Plc’s EPS estimate?
Autolus Therapeutics Plc’s EPS estimate is -0.23.
How many shares outstanding does Autolus Therapeutics Plc have?
Autolus Therapeutics Plc has 266,143,280 shares outstanding.
What happened to Autolus Therapeutics Plc’s price movement after its last earnings report?
Autolus Therapeutics Plc reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.214. Following the earnings report the stock price went down -9.333%.
Which hedge fund is a major shareholder of Autolus Therapeutics Plc?
Currently, no hedge funds are holding shares in AUTL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Autolus Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.68 (380.00% Upside)
$7.68 (380.00% Upside)
Blogger Sentiment
Bullish
AUTL Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 147.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 19.0%
Last 30 Days ▲ 31.2%
Last 30 Days ▲ 31.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.98%
12-Months-Change
Fundamentals
Return on Equity
-60.52%
Trailing 12-Months
Asset Growth
-20.01%
Trailing 12-Months
Company Description
Autolus Therapeutics Plc
Autolus Therapeutics is a clinical-stage biopharmaceutical company focused on developing next-generation T cell therapies for the treatment of cancer. The company specializes in engineered T cell therapies, leveraging its proprietary technology platforms to create innovative products aimed at addressing significant unmet medical needs in oncology. Autolus is dedicated to advancing its pipeline of product candidates through clinical trials, primarily targeting hematological malignancies and solid tumors.
AUTL Company Deck
AUTL Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
While the company has seen a successful launch of Obe-cel in the U.S. with significant market penetration and expansion into new clinical areas, financial challenges such as high cost of sales and increased operational losses present notable challenges. However, the company is well-capitalized to continue its growth and expansion strategies.View all AUTL earnings summariesAUTL Stock 12 Month Forecast
Average Price Target
$7.68
▲(380.00% Upside)
Technical Analysis
Tvardi Therapeutics
―
Larimar Therapeutics
―
Benitec Biopharma
―
Diamedica Therapeutics
―
Contineum Therapeutics, Inc. Class A
―
Ownership Overview
―
Insiders
8.69% Mutual Funds
39.94% Other Institutional Investors
50.66% Public Companies and Individual Investors